Investornewsbreaks TC Biopharm Holdings PLC (NASDAQ: TCBP) Announces ADS Ratio Change Effective Feb. 10

(MENAFN- Investor Brand Network) TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotechnology company, announced a change in the ratio of its American Depositary Shares (“ADSs”) to ordinary shares from 1 ADS representing 200 ordinary shares to 1 ADS representing 4,000 ordinary shares, effective Feb. 10, 2025. The adjustment will function as a 1-for-20 reverse ADS split but will not affect the total number of underlying ordinary shares. The bank of New York Mellon, the company's depositary bank, will manage the exchange, with fractional entitlements aggregated and sold, and proceeds distributed to holders. TC BioPharm expects the ADS trading price to rise proportionally but does not guarantee specific price outcomes.

To view the full press release, visit:

About TC BioPharm Holdings PLC

TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial for OmnImmune(R) in treatment of acute myeloid leukemia using the company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. For more information about the company, visit .

NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company's newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN06022025000224011066ID1109177581